TG Therapeutics (NASDAQ:TGTX – Free Report) had its price objective increased by HC Wainwright from $45.00 to $49.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other analysts have also recently issued reports on the stock. The Goldman Sachs […]
TG Therapeutics (NASDAQ:TGTX – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Briefing.com reports. The company had revenue of $63.47 million during the quarter, compared to analyst estimates of $54.60 million. TG Therapeutics had a net […]
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 13,983 call options on the stock. This is an increase of approximately 88% compared to the average volume of 7,433 call options. Insider Activity In related news, Director Laurence N. Charney sold 22,000 […]
Avaii Wealth Management LLC cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 13.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,283 shares of the biopharmaceutical company’s stock after selling 4,739 shares during the […]